You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Low T cell numbers

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Poor Thymic Function, Immunodeficiency, Athymia Trial (biological, procedure, drug)

Approved for marketing
  • Poor Thymic Function
  • +5 more
  • Cultured Thymus Tissue
  • +2 more
  • (no location specified)
Mar 23, 2022

T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023

NSCLC Trial (KB-GDT-01)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • KB-GDT-01
  • (no location specified)
Sep 29, 2023

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

PD1+T Cell Expression in Peripheral Blood for Cardiac Function

Recruiting
  • PD1
  • Acute Myocardial Infarction
  • PD1+ T Cell Expression
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Feb 22, 2022

Healthy Volunteers Trial in Paris (ILT101, Placebo)

Completed
  • Healthy Volunteers
  • Paris, France
    Clinical Investigation Center Paris Est Hôpital Universitaire Pi
Dec 10, 2021

Mycosis Fungoides, Cutaneous T Cell Lymphoma Trial (Low-dose total-skin electron-beam therapy, Phototherapy)

Not yet recruiting
  • Mycosis Fungoides
  • Cutaneous T Cell Lymphoma
  • Low-dose total-skin electron-beam therapy
  • Phototherapy
  • (no location specified)
Jan 24, 2022

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)

Active, not recruiting
  • Myelodysplastic Syndromes (MDS)
  • Acute Myelogenous Leukemia (AML)
  • low dose 5'-azacitidine
  • Basking Ridge, New Jersey
  • +6 more
Dec 1, 2022

Cutaneous T-cell Lymphoma Trial in New York (Bexarotene, Total Skin Electron Beam (TSEB))

Recruiting
  • Cutaneous T-cell Lymphoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Sep 19, 2022

Hematopoietic Stem Cell Transplantation Trial in Nantes (IL2, Zoledronic Acid)

Recruiting
  • Hematopoietic Stem Cell Transplantation
  • IL2
  • Zoledronic Acid
  • Nantes, France
    Nantes Uh
Mar 29, 2022

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

GVHD Trial in Hackensack (Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose

Terminated
Has Results
  • Graft Versus Host Disease
  • Cyclophosphamide and Sirolimus
  • +3 more
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Feb 4, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2022

Oropharyngeal Cancer Trial in Canada (Radiation, Cisplatin)

Active, not recruiting
  • Oropharyngeal Cancer
  • Prince George, British Columbia, Canada
  • +13 more
Dec 12, 2022

Objective Response Rate Trial in Hangzhou (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Recruiting
  • Objective Response Rate
  • CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 5, 2021

Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism Trial in Belgium, Netherlands (Mesenchymal stem

Recruiting
  • Graft-versus-host Disease
  • +2 more
  • Mesenchymal stem cells
  • Edeghem, Antwerpen, Belgium
  • +11 more
Sep 19, 2022

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023

Multiple Myeloma Trial in Suzhou (clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells)

Recruiting
  • Multiple Myeloma
  • clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 22, 2021

Sickle Cell Disease Trial in Canada, United States (Alemtuzumab intravenously, low dose total body irradiation, Sirolimus)

Recruiting
  • Sickle Cell Disease
  • Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
  • Washington, District of Columbia
  • +5 more
Mar 2, 2022

Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,

Active, not recruiting
Has Results
  • Stage I Multiple Myeloma
  • +2 more
  • Chicago, Illinois
  • +4 more
Sep 3, 2022

Primarily Resectable Pancreatic Cancer Trial in Heidelberg (neoadjuvant photon radiation)

Completed
  • Primarily Resectable Pancreatic Cancer
  • neoadjuvant photon radiation
  • Heidelberg, Germany
  • +1 more
Jun 7, 2021

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)

Recruiting
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • +10 more
  • Intensity-Modulated Radiation Therapy
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 8, 2022

Idiopathic CD4-Positive, T-Lymphocytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • Idiopathic CD4-Positive
  • T-Lymphocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023